Lionheart Health, Inc., through Leonhardt Ventures LLC, has filed a provisional patent application for a bioelectric stimulation platform designed to enhance peptide uptake and biological effectiveness across multiple delivery methods. The technology addresses persistent challenges in translating promising peptide biology into consistent real-world outcomes, particularly in longevity medicine where delivery and bioavailability remain limiting factors.
Current peptide delivery methods face significant efficiency losses, with up to 70% of intravenous delivery lost and up to 99.9% of oral and topical deliveries failing to reach target tissues effectively. The new platform applies controlled bioelectric stimulation to improve absorption and signaling efficiency across key healthspan-related pathways including klotho, sirtuins, sestrins, apelin, and related proteins. Early experimental data indicates improvements of up to 300 percent, potentially enabling lower dosing while maintaining or increasing therapeutic impact.
The patent builds on decades of bioelectric medicine research conducted by Leonhardt Ventures and expands Lionheart Health's proprietary platform for modulating cellular environments to optimize peptide and protein activity. The technology is designed to enhance barrier transport, receptor interaction, and downstream tissue-level effects through mechanisms including enhanced transmembrane transport, improved barrier permeability, receptor sensitization, and intracellular trafficking optimization.
Howard J. Leonhardt, Executive Chairman, Inventor and co-CEO of Lionheart Health, Inc. and CEO of Leonhardt Ventures LLC, stated that this filing represents a major step forward in making advanced peptide-based longevity interventions more efficient, predictable, and scalable. By combining peptides with bioelectric signaling, the company believes it can unlock significantly greater biological impact at lower doses, across multiple routes of administration.
The patent claims encompass oral, topical, and injectable peptide delivery enhanced by targeted bioelectric stimulation, with special emphasis on peptides that enhance Klotho activity, a protein closely linked to aging regulation and cellular resilience. Lionheart Health, recognized for its leadership in klotho-based longevity research and recently named a Top 40 semifinalist in the XPRIZE Healthspan competition, holds multiple issued patents related to klotho technologies with additional applications pending.
The newly filed intellectual property strengthens Lionheart Health's position at the intersection of bioelectric medicine and peptide therapeutics, creating opportunities for next-generation longevity and wellness protocols, licensed clinical and research applications, and integration into future devices and clinical studies. The company plans to incorporate the technology into selected upcoming healthspan initiatives and investigational protocols while pursuing strategic partnerships and licensing opportunities. More information about the company's work can be found at http://www.lionhearthealthstim.com and http://www.LionheartLongevity.com.
